Annexon Inc. is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.
At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications. Complementing this program is ANX007, which targets C1s and is being evaluated in ophthalmic disorders such as geographic atrophy secondary to age-related macular degeneration. Preclinical studies and early human data have demonstrated the potential of these antibodies to modulate complement activity with favorable safety profiles, supporting further development in both inpatient and outpatient settings.
Founded in 2015 on the strength of foundational research from the University of Pennsylvania, Annexon is headquartered in San Francisco, California. The company was established by a team of scientists and industry veterans with deep expertise in the complement system and translational neuroscience. William B. Wetsel Jr., Ph.D., serves as President and Chief Executive Officer, guiding Annexon’s strategic initiatives and collaborations with academic partners, patient advocacy groups, and regulatory authorities.
Annexon’s clinical development programs span multiple geographies, with active sites in North America, Europe and Asia. By focusing on rare diseases with significant unmet medical need, the company seeks to deliver first-in-class therapies that can modify disease progression and improve patient outcomes. As a NASDAQ-listed entity (ANNX), Annexon continues to advance its portfolio toward pivotal milestones and potential regulatory approvals.
AI Generated. May Contain Errors.
